Chemoproteomic selectivity profiling of TAK285 in NALM6 cells

ABSTRACT: We used dose-dependent chemoproteomic competition assays to profile the proteome-wide target binding and selectivity of the kinase inhibitor TAK285.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell

DISEASE(S): Acute Leukemia

SUBMITTER: Severin Lechner  

LAB HEAD: Georg E. Winter

PROVIDER: PXD064676 | Pride | 2025-10-06

REPOSITORIES: Pride